Department of Clinical Pharmacy, Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Dermatol Ther. 2022 Jun;35(6):e15450. doi: 10.1111/dth.15450. Epub 2022 Mar 22.
Alopecia areata (AA) is a recurrent chronic disease that affects hair follicles and results in hair loss. Make an increase in the number, thickness, and length of eyelashes is an important side effect of latanoprost eye drop. This study aimed to evaluate the effect of hypertrichosis property of latanoprost in the treatment of scalp AA. In this randomized double-blind placebo-controlled trial, 30 participants with scalp AA assigned to receive either topical latanoprost 0.005% solution or placebo for 12 weeks. In both arms, patients also received clobetasol 0.05% cream in isopropyl alcohol (1:1). The hair loss area pictured at baseline and the end of the fourth, eighth, and twelfth weeks. According to the images, the dermatologist assessed the hair loss area, hair density, and the severity of alopecia. Latanoprost significantly increased hair density (37.2 ± 26.1 vs. 14.6 ± 18.6) and regrowth (58.3 ± 39.3 vs. 21.6 ± 24.1) based on the Severity of Alopecia Tool (SALT) system compared to the control group (p = 0.03 and 0.02, respectively). However, there were no significant differences between the two groups in reduction in the hair loss area and SALT, and the incidence of side effects (p = 0.718, 0.262, and ≥0.99, respectively). Results showed the acceptable safety and efficacy of latanoprost 0.005% solution to increase hair density and regrowth. So, it could be safely used for the management of scalp AA.
斑秃（AA）是一种反复发作的慢性疾病，影响毛囊，导致毛发脱落。增加睫毛的数量、厚度和长度是拉坦前列素滴眼液的一个重要副作用。本研究旨在评估拉坦前列素的多毛特性在头皮 AA 治疗中的效果。在这项随机、双盲、安慰剂对照试验中，30 名头皮 AA 患者被分配接受局部使用 0.005%拉坦前列素溶液或安慰剂治疗 12 周。在两个治疗组中，患者还接受了异丁醇（1:1）中的 0.05%卤倍他索乳膏。在基线和第 4、8 和 12 周结束时拍摄头皮脱发区域的图片。根据图像，皮肤科医生评估脱发面积、毛发密度和脱发严重程度。与对照组相比，拉坦前列素显著增加了毛发密度（37.2±26.1 对 14.6±18.6）和再生（58.3±39.3 对 21.6±24.1），基于脱发严重程度评估工具（SALT）系统（分别为 p=0.03 和 0.02）。然而，两组之间在脱发面积和 SALT 减少以及不良反应发生率方面均无显著差异（p=0.718、0.262 和≥0.99，分别）。结果表明，0.005%拉坦前列素溶液具有可接受的安全性和增加毛发密度和再生的疗效。因此，它可安全用于头皮 AA 的治疗。
